What is a stock summary page? Click here for an overview.
Business Description
4D Molecular Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US35104E1001
Share Class Description:
FDMT: Ordinary SharesDescription
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.27 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.34 | |||||
| Beneish M-Score | -124.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -88.5 | |||||
| 3-Year EBITDA Growth Rate | -10.9 | |||||
| 3-Year EPS without NRI Growth Rate | -5.1 | |||||
| 3-Year FCF Growth Rate | 3.1 | |||||
| 3-Year Book Growth Rate | 4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -9.02 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 314.04 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.87 | |||||
| 9-Day RSI | 56.76 | |||||
| 14-Day RSI | 50.75 | |||||
| 3-1 Month Momentum % | -20.71 | |||||
| 6-1 Month Momentum % | -54.66 | |||||
| 12-1 Month Momentum % | -84.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.92 | |||||
| Quick Ratio | 14.92 | |||||
| Cash Ratio | 14.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.4 | |||||
| Shareholder Yield % | -218.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -507678.38 | |||||
| Net Margin % | -434778.38 | |||||
| FCF Margin % | -373975.68 | |||||
| ROE % | -31.42 | |||||
| ROA % | -29.2 | |||||
| ROIC % | -211.24 | |||||
| 3-Year ROIIC % | -384.4 | |||||
| ROC (Joel Greenblatt) % | -539.98 | |||||
| ROCE % | -35.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3340 | |||||
| PB Ratio | 0.3 | |||||
| Price-to-Tangible-Book | 0.3 | |||||
| EV-to-EBIT | 1.33 | |||||
| EV-to-EBITDA | 1.38 | |||||
| EV-to-Revenue | -6751.03 | |||||
| EV-to-Forward-Revenue | 4.54 | |||||
| EV-to-FCF | 1.81 | |||||
| Price-to-GF-Value | 47.71 | |||||
| Price-to-Net-Current-Asset-Value | 0.4 | |||||
| Price-to-Net-Cash | 0.41 | |||||
| Earnings Yield (Greenblatt) % | 75.19 | |||||
| FCF Yield % | -89.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FDMT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
4D Molecular Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.037 | ||
| EPS (TTM) ($) | -2.98 | ||
| Beta | 3.21 | ||
| 3-Year Sharpe Ratio | -0.01 | ||
| 3-Year Sortino Ratio | -0.04 | ||
| Volatility % | 39 | ||
| 14-Day RSI | 50.75 | ||
| 14-Day ATR ($) | 0.305669 | ||
| 20-Day SMA ($) | 3.01325 | ||
| 12-1 Month Momentum % | -84.3 | ||
| 52-Week Range ($) | 2.235 - 28.9269 | ||
| Shares Outstanding (Mil) | 46.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
4D Molecular Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4D Molecular Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
4D Molecular Therapeutics Inc Frequently Asked Questions
What is 4D Molecular Therapeutics Inc(FDMT)'s stock price today?
The current price of FDMT is $3.34. The 52 week high of FDMT is $28.93 and 52 week low is $2.24.
When is next earnings date of 4D Molecular Therapeutics Inc(FDMT)?
The next earnings date of 4D Molecular Therapeutics Inc(FDMT) is 2025-05-09 Est..
Does 4D Molecular Therapeutics Inc(FDMT) pay dividends? If so, how much?
4D Molecular Therapeutics Inc(FDMT) does not pay dividend.
Guru Commentaries on NAS:FDMT
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers